How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Mutation Detection in ctDNA or CTC - Highly sensitive, fast and cost-effective detection of gene modifications and mutations in ctDNA or CTC

Organization name

PROvendis GmbH


Particularly in oncology, determination of gene mutation statuses serves as a biomarker to guide rational therapeutic decisions. Due to patient safety sequential biopsies or biopsies of multiple tumor lesions are not routinely performed.

Scientists of the University of Duisburg-Essen developed a platform, which facilitates the detection of deletions and insertions as well as point mutations in target genes from a variety of sources against a huge background of wild type alleles, making a clear “Yes” or “No” output possible and thereby simplifying therapeutic decisions.

Neither expensive and complicated equipment nor specialized personnel is needed. The assay is robust and applicable in all laboratories equipped with an RT-PCR machine. It can easily be established for point of care (PoC) purposes.

This sensitive technology now enables clinicians to be independent of the scarce resource “tissue biopsy”. By using blood (ctDNA, cfDNA or CTC) it opens new non-invasive possibilities for monitoring the mutation status of patients before and during treatment as well as to detect disease relapse early.

Commercial Opportunities

This invention allows an easy and economical way for the stratification of patients (e.g. for treatment with tyrosine-kinase-inhibitors) with unique sensitivity. Based on RT-PCR, the technical requirements are conventional and worldwide accessible. The non-invasive analysis of free DNA from plasma/serum samples is possible and facilitates continuous monitoring of treatment response.

Current Status  

Platform technology established for common oncogenic mutations with similar impressive sensitivities - BRAF (V600E), EGFR (DelEx19, L858R, T790), KRAS (codon 12/13/61).

On behalf of University of Duisburg-Essen, PROvendis offers access for commercial use in terms of a license as well as research collaborations. In case of interest, we are pleased to inform you about the current patent status.

A European and a US patent have already been granted, other applications are pending.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries